What Alfugen Treats: Main Uses and Benefits

Alfugen is used for the chronic symptomatic management of Benign Prostatic Hyperplasia (BPH) in adult men, a condition involving an enlarged prostate. This medication is utilized to manage associated urinary symptoms that can create physiological strain and interfere with daily functioning.

The application of this treatment addresses both voiding difficulties and storage symptoms. It is used for managing voiding symptoms such as urinary hesitancy, a slow or weak urine stream, straining to urinate, and the sensation of incomplete bladder emptying. It is also used to address storage symptoms including urgency, frequency, and disruptive nighttime waking (nocturia). This supportive management is often employed during phases when symptoms become more noticeable.

The medication supports the reduction of the overall symptom load and helps maintain stability when symptoms are more prominent. This approach assists with more comfortable and functional urination and may contribute to improved rest and sleep quality, providing supportive relief when symptoms interfere with routine activities.

---

Quick Fact: Relief for Lower Urinary Tract Symptoms (LUTS) secondary to BPH.

Regulatory References

1. MedlinePlus Drug Information

Alfugen (Alfuzosin hydrochloride) has specific regulatory criteria that strictly define the patient population eligible for its use. The official labeling is organized around prohibitions, restrictions, and conditional use tied to patient demographics and physiological status.

Eligibility Scope

Category	Official Regulatory Status
Populations for whom use is allowed	Adult Men with signs and symptoms of Benign Prostatic Hyperplasia (BPH).
Populations for whom use is contraindicated	Moderate or Severe Hepatic Impairment (Child-Pugh B and C).
	Co-administration with Potent CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir).
	Known Hypersensitivity to alfuzosin or formulation components.
Age-related eligibility rules	Pediatric Population (under 18 years): Not indicated for use; efficacy has not been demonstrated.
Condition-specific eligibility rules	Severe Renal Impairment (Creatinine Clearance <30 mL/min): Use not recommended due to limited safety data.
	History of Orthostatic Hypotension: Contraindicated (in certain regions).
	Pre-existing Coronary Artery Disease: Use requires caution; discontinue if angina appears or worsens.
Pregnancy and lactation eligibility status	Women (general): Not indicated for use in female patients.

Eligibility Classifications

Category	Classification Details
Eligibility severity classification	Contraindicated (Absolute prohibition); Not Indicated (Efficacy/Safety not established or inappropriate population); Caution Should Be Exercised (Conditional use).
Regulatory basis	Defined under FDA Prescribing Information and SmPC Contraindications and Warnings sections.

These official statements define who can and cannot use Alfugen by restricting its use to a single gender and age group, while formally prohibiting its use based on organ function (moderate/severe liver impairment) and concurrent medication use that raises blood levels. Further restrictions apply to individuals with severe kidney impairment, emphasizing that all patient eligibility is strictly defined by regulatory documents.

Interactions with other medicines and products

The interaction profile of Alfugen (Alfuzosin hydrochloride) is officially documented based on two primary risks: elevated drug exposure due to metabolic interference and enhanced hypotensive effects.

Contraindicated Combinations

Co-administration with potent CYP3A4 inhibitors, such as Ketoconazole, Itraconazole, or Ritonavir, is formally contraindicated. These drugs substantially increase Alfuzosin blood levels (exposure), raising the risk of adverse reactions. Alfugen is also contraindicated for co-administration with other alpha-1 adrenergic antagonists due to the high risk of severe hypotension.

Clinically Significant Pharmacodynamic Interactions

Combining Alfugen with other vasodilating agents carries an elevated risk of symptomatic hypotension. This includes antihypertensive medications, nitrates, and Phosphodiesterase-5 (PDE5) inhibitors (e.g., Sildenafil). Caution is advised with drugs that prolong the QT interval.

Food and Procedural Constraints

To ensure consistent and required drug exposure, regulatory documents specify that Alfugen must be taken immediately after the same meal each day, as absorption is significantly reduced under fasting conditions. Furthermore, in Europe, regulatory documents recommend withdrawal 24 hours prior to procedures involving general anesthetics to mitigate the risk of blood pressure instability.

Population-Specific Interaction Notes

Alfugen is contraindicated in patients with moderate or severe hepatic impairment. This restriction is due to reduced drug clearance, which causes three- to four-fold higher plasma concentrations, effectively functioning as a severe interaction risk.

Selective Alpha-1 Receptor Blockade

Alfugen functions as a selective and competitive antagonist of post-synaptic alpha-1 adrenergic receptors (alpha1-ARs). The compound demonstrates a preferential binding affinity for the alpha1A receptor subtype, which is highly expressed on the smooth muscle cells of the prostate capsule and bladder neck. Alfugen's binding to these receptors inhibits the signal cascade that normally mediates sympathetically controlled muscle contraction.

---

Modulation of Urethral Resistance

This blockade causes the relaxation of smooth muscle tone in the lower urinary tract, a peripheral physiological response. The interruption of sympathetic signaling at the cellular level leads to a direct reduction in the dynamic component of resistance exerted by the prostatic smooth muscle on the urethra. The resulting physiological change is a reduction in the dynamic resistance at the bladder outlet, which generates the physiological capacity for increased urinary flow velocity and measurable adjustments in urodynamic parameters.

How to Use Alfugen: Administration Guidelines

This section outlines the usage and administration instructions for Alfugen (Alfuzosin hydrochloride 10 mg extended-release tablets).

---

Administration Scope

Instruction Category	Administration Detail
Route of administration	Oral (swallowed by mouth)
Dosing schedule	One 10 mg extended-release tablet once daily.
Timing in relation to meals	Must be taken immediately after the same meal each day; absorption is significantly lower if taken on an empty stomach.
Preparation requirements	The tablet must be swallowed whole with water.
Special procedural conditions	The tablet must not be crushed, chewed, split, or divided.
Missed-dose rules	If a dose is missed, skip the missed dose and continue with the next scheduled dose at the usual time; do not take two doses to make up for a missed one.

---

Population-Specific Use Rules

Instruction Category	Application Detail
Older Adults	No dose adjustment is typically necessary for patients over 65 years.
Hepatic Impairment	Contraindicated (should not be used) in patients with moderate or severe liver impairment.
Pediatric Patients	Not indicated for use in the pediatric population.

---

The administration protocol emphasizes the oral, once-daily, 10 mg regimen. This use protocol is defined by the requirement to take the tablet with food and the instruction to swallow the extended-release tablet intact, ensuring the usage pattern is followed precisely.

Research Evidence / Overview of Studies for Alfugen

---

Evidence for Use in Managing Chronic BPH Symptoms

Research exploring Alfugen was studied for its use in adult men with Lower Urinary Tract Symptoms (LUTS) associated with an enlarged prostate, known as Benign Prostatic Hyperplasia (BPH). The core evidence is based on short-term, placebo-controlled Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time and outcomes related to physical discomfort. Researchers examined standardized symptom scores (like the International Prostate Symptom Score, or IPSS) and functional measures, such as maximum urine flow rate ( Q max), to track data during defined time intervals.

Systematic reviews and meta-analyses, which combine data from multiple RCTs, described how the measured IPSS scores and functional flow rates evolved during the study period in the observed populations. Findings describe patterns observed in the studies related to outcomes reflecting daily functioning or activity level. Research has also explored long-term urological outcomes, such as rates of Acute Urinary Retention (AUR) and the rate of BPH-related surgical intervention. This evidence contributes to the broader evidence landscape and contextualizes how patients reported their experience during the study period.

---

Evidence for Use After Acute Urinary Retention

Alfugen was studied for its application following an acute, disruptive episode where BPH-related symptoms led to the sudden inability to urinate, requiring a catheter (Acute Urinary Retention, or AUR). The primary focus of these specific trials was on the outcome of the trial without catheter (TWOC), which measures the patient's ability to urinate on their own after the catheter is removed. Research examined the tracked rate of immediate re-catheterization and the rate of early surgical intervention in the studied group over the short follow-up period.

---

Research Gaps and What is Still Uncertain

While an extensive body of evidence contributes to the broader evidence landscape, several key limitations remain. Follow-up durations were limited in the original controlled studies, and comparative evidence is lacking for outcomes tracked beyond 12 months. Research describes what is known regarding the maintenance of symptom patterns, but long-term outcomes are not fully established. For instance, while some studies explored outcomes monitoring physiological strain or stress, the findings were mixed regarding the measured rate of certain late-stage BPH progression endpoints, such as the specific long-term rate of BPH-related surgical intervention.

Common questions about Alfugen (FAQ)

Q: Does Alfugen shrink the prostate?

A: No, Alfugen does not shrink the size of the prostate. It belongs to a class of medicines called alpha-blockers. It works by relaxing muscles of the bladder and prostate to allow urine to flow more easily. This helps in relieving the symptoms of an enlarged prostate.

Q: Can Alfugen cause erectile dysfunction?

A: No, Alfugen does not typically cause erectile dysfunction. It may, in some cases, help improve this condition. However, this medicine may cause a painful erection (priapism) which does not go away. If priapism is not treated immediately, it can lead to permanent damage and future inability to get an erection.

Q: When should I take Alfugen?

A: Alfugen should be taken after a meal at the same time each day. Do not cut, crush, or chew the medicine; swallow it whole with water.

Q: Does Alfugen have any effect on the liver?

A: In very rare cases, your liver may be affected, which can cause an abnormality in liver function tests. If you already have liver disease, inform your doctor before starting this medication. Your doctor will assess your condition and may prescribe a lower dose of Alfugen once or twice daily.

Q: Can Alfugen be taken by elderly people?

A: Yes, it can be taken by elderly or old people, but caution is advised. Regular monitoring may be required, especially if the patient also has high blood pressure.

Q: Can Alfugen affect my eyes?

A: In rare cases, Alfugen may cause abnormal vision. It is important to know that this medicine may cause complications during surgery for cataracts. You must inform your doctor before any surgery that you are taking Alfugen. Your doctor may perform the surgery differently to help prevent complications.

Q: Is it safe to take sildenafil or vardenafil along with Alfugen?

A: Extreme care should be taken if you are taking sildenafil or vardenafil (medicines used to treat erectile dysfunction) along with Alfugen. The combination may cause a significant and potentially serious decrease in blood pressure. You must inform your doctor if you are taking these medicines.

Q: What can patients do to help with discomfort and side effects due to Alfugen?

A: Alfugen may lower your blood pressure, especially when you suddenly stand up after lying down. You may feel dizzy or faint, and you should, therefore, get up slowly from bed or a chair. This medicine may also impair your reactions, so avoid driving or engaging in hazardous activities until you know how this medicine will affect you.

How to Store and Dispose of Alfugen?

The storage and disposal of Alfugen (Alfuzosin hydrochloride extended-release tablets) must strictly follow official regulatory guidelines to maintain its stability and ensure public safety.

Storage Requirements

Alfugen must be kept in its original container, which should be tightly closed. Store the medication at controlled room temperature, typically below 30 °C, and ensure it is protected away from light and excess moisture [SmPC; MedlinePlus]. A mandatory handling rule is that the extended-release tablets must not be crushed, chewed, or powdered [FDA Prescribing Information]. The product should always be kept out of the sight and reach of children [SmPC].

Disposal Instructions

Do not use Alfugen past the expiry date printed on the packaging. Unused or expired medication must not be thrown away in household waste or flushed down the toilet [HPRA SmPC]. Disposal should align with local regulations, which often involve returning the product to a pharmacist or utilizing an official drug take-back program [FDA].